Xeloda-Warfarin Black Box Warning To Be Subject Of Roche Letter To Doctors
Executive Summary
Roche is preparing a letter to physicians highlighting a black box warning about interactions between Xeloda (capecitabine) and warfarin following FDA's Sept. 7 approval of the labeling change.
You may also be interested in...
Roche Xeloda Combo With Taxotere Approved; Phase IV Dosing Study Planned
Roche will submit the protocol for a Phase II study comparing three different dose regimens for Xeloda (capecitabine) by January 2002 as one of its postmarketing commitments following the Sept. 7 supplemental approval of the agent for use in combination with Aventis' Taxotere (docetaxel) to treat metastatic breast cancer.
Roche Xeloda Combo With Taxotere Approved; Phase IV Dosing Study Planned
Roche will submit the protocol for a Phase II study comparing three different dose regimens for Xeloda (capecitabine) by January 2002 as one of its postmarketing commitments following the Sept. 7 supplemental approval of the agent for use in combination with Aventis' Taxotere (docetaxel) to treat metastatic breast cancer.
Roche Xeloda
"Dear Doctor" letter issued warning of potential interaction of capecitabine with coumarin derivatives. "The time of occurrence of these events (altered coagulation parameters and/or bleeding) ranged from several days to several months after starting Xeloda therapy and, in isolated cases, occurred within one month after the last dose," the March letter states. "Patients taking Xeloda with concomitant coumarin derivatives should be monitored regularly for alterations in their coagulation parameters (PT or INR)." Language describing the coagulopathy has been added to the "Warnings" section of labeling, and a description of the drug-drug interactions has been added to the "Precautions" section